Luspatercept, Suppliers & Bulk Manufacturers
Available Forms: Lyophilized powder for subcutaneous injection
Available Strengths: 25 mg, 75 mg
Reference Brands: Reblozyl
Category: Anemia
Luspatercept (Reblozyl) is an FDA and EMA-approved biologic used to treat anemia in beta thalassemia and MDS patients. It reduces transfusion needs by enhancing red blood cell production. Offered in GMP-certified form, ideal for pharma B2B buyers, distributors, and exporters. Contact us for bulk supply and regulatory support. Luspatercept, is available in Lyophilized powder for subcutaneous injection and strengths such as 25 mg, 75 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Luspatercept, is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.
| Technical Specifications & Supply Details | |
|---|---|
| Lead Time | 7 to 60 days (depending on batch size & schedule) |
| MOQ | As per manufacturer’s batch size |
| COA | Available with every batch |
| Regulatory Dossier / DMF | Available upon request |
| Export Documentation | FSC, COA, Manufacturing License, Product Permission |
| Standards | IP, BP, USP |
| Certifications | WHO-GMP, EU-GMP, USFDA (as applicable) |
Luspatercept, can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.
Product Description:
Luspatercept is a groundbreaking erythroid maturation agent used to treat anemia in patients with beta thalassemia and myelodysplastic syndromes (MDS). Marketed under the brand name Reblozyl, it is approved by the FDA and EMA for reducing red blood cell transfusion dependence. Luspatercept is a recombinant fusion protein administered via subcutaneous injection and produced under strict GMP compliance. Ideal for pharmaceutical distributors, wholesalers, and B2B partners seeking high-demand biologics. We offer global bulk supply, regulatory support, and competitive pricing for Luspatercept. Partner with us for reliable sourcing and efficient delivery. Contact us now for Luspatercept export and distribution solutions.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Frequently Asked Questions
Luspatercept is used to treat anaemia in adults with beta-thalassemia who require regular red blood cell transfusions. It is also used in certain patients with myelodysplastic syndromes (MDS) to reduce the need for blood transfusions.
It is made from a recombinant fusion protein that binds to specific TGF-beta superfamily ligands, helping enhance late-stage red blood cell maturation in the bone marrow.
The trade name is Reblozyl.
Luspatercept (Reblozyl) is manufactured by Bristol Myers Squibb in collaboration with Acceleron Pharma.
The generic name is Luspatercept-aamt.
The brand name is Reblozyl.
It is manufactured in the United States and other approved Bristol Myers Squibb production sites globally.
Related Products
Epoetin Alfa
Strength:
1,000 IU, 2,000 IU, 4,000 IU, 10,000 IU, 40,000 IU
Form: injection (prefilled syringe)
Reference Brands: EPOGEN (USA), PROCRIT (USA)
View Details
Ferumoxytol Injection
Strength:
30 mg/mL
Form: Injection
Reference Brands: Feraheme (USA)
View Details
Deferoxamine
Strength:
500 mg/vial, 2 g/vial
Form: Lyophilized powder for injection
Reference Brands: Desferal
View Details
Deferasirox
Strength:
125 mg, 250 mg, 500 mg
Form: Tablets for Oral Suspension
Reference Brands: Exjade, Jadenu (film-coated)
View DetailsQuick Response Guaranteed | Verified Suppliers
